Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung CancerYi‐Long Wu, Roy S. Herbst, Christian Grohé et al.|New England Journal of Medicine|2020Cited by 1.7k
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA TrialRoy S. Herbst, Masahiro Tsuboi, Yi‐Long Wu et al.|Journal of Clinical Oncology|2023Cited by 386